Venlo, the Netherlands, Aug. 28, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca’s future therapies being developed to address chronic diseases. Under the agreement, QIAGEN will develop and validate a genotyping assay using QIAGEN’s syndromic testing platform QIAstat-Dx. The test will enable specialty care providers to poten ...

Per an article by Seeking Alpha (“SA”), AstraZeneca (AZN) dismissed a media report that claimed it may shift its vaccine manufacturing site from the U.K. to the United States.This reported denial comes in response to last week's article by the Financial Times (“FT”), which claimed that discussions between AstraZeneca and the U.K. government concerning state aid had hit an impasse. This report, which cited multiple unknown sources, claimed that chancellor Rachel Reeves was looking to reduce the amount of sta ...

AstraZeneca (AZN) announced that the FDA expanded the label of its blockbuster cancer drug Imfinzi for a fourth indication in lung cancer.The FDA approved Imfinzi in combination with platinum-based chemotherapy for treating adults with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) with no known EGFR mutations or ALK rearrangements. While the Imfinzi-chemotherapy combo will be administered before surgery, Imfinzi monotherapy will be given after surgery.This approval is based on data fr ...

AstraZeneca (AZN) announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain patients with primary advanced or recurrent endometrial cancer, also known as uterine cancer.The eligible patient population for receiving Imfinzi plus chemotherapy as a first-line treatment followed by Lynparza and Imfinzi are patients with mismatch repair proficient (pMMR) disease. For those who suffer from mismatch rep ...

In a market characterized by uncertainty and volatility, it's increasingly rare to find stocks that are weathering the storm and thriving. Yet, a select few from various sectors are doing just that—hitting all-time highs even as the broader market indices attempt to regain their footing. These three stocks, outlined below, showcase remarkable relative strength, which could signal potential buying opportunities for discerning investors. But what is driving this outperformance, and can it be sustained? Let's ...

The outlook for pharmaceutical stocks has been mixed in the last five years. During the pandemic, the early-movers in the vaccine race gained as compared to others. However, sentiments turned significantly negative for the pharmaceutical sector in a post-covid world. I believe that pharmaceutical stocks are poised for a strong comeback in the next 12 to 24 months.There are two major reasons for this view. First, the world faces macroeconomic and geopolitical headwinds. It’s likely that the markets will be v ...

For Immediate ReleasesChicago, IL – August 6, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca (AZN) , Ionis (IONS) and Sanofi (SNY) .Here are highlights from Tuesday’s Analyst Blog:How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?AstraZeneca announced strong second-quarter results on J ...

The winners of today might not compete in the lucrative new segment of tomorrow.Industry insiders often have perspectives that are invaluable for investors to learn. In that vein, AstraZeneca's (AZN 0.75%) CEO, Pascal Soriot, recently made some interesting remarks during the company's second-quarter earnings call with analysts.Soriot's view has major implications for how investors should approach stocks like AstraZeneca, as well as weight loss drug leaders like Novo Nordisk and Eli Lilly -- not to mention b ...

These stocks arguably deserve more respect from investors.The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely.Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to buy right now. Here's why they picked AstraZeneca (AZN 0.38%), Pfizer (PFE 3.21%), and Viatris (VTRS 2.08%).A healthcare behemoth that's trading at a discountDavid Jagielski (AstraZeneca): You wou ...

AstraZeneca TodayAZNAstraZeneca$78.52 -1.19 (-1.49%) 52-Week Range$60.47▼$80.86Dividend Yield2.46%P/E Ratio38.49Price Target$88.00Add to WatchlistAstraZeneca PLC NASDAQ: AZN is a United Kingdom-based healthcare firm and the sixth-largest pharmaceutical company in the world by market capitalization. So far, in 2024, the firm has outperformed the market and its sector, achieving a total return of 17%. The total return of the SPDR S&P Pharmaceuticals ETF NYSEARCA: XPH is 4%.Let's review the company’s business ...